Category: unreliable findings

Duke University lung researchers cough up fourth retraction, due to “inconsistent” data

Journal of Applied PhysiologyThe Journal of Applied Physiology has retracted a 2012 respiratory study after the authors found “inconsistent” data that “could not be traced to their source.” It’s the fourth retraction for two of the researchers, including Erin Potts-Kant, who was arrested in 2013 for embezzling more than $14,000 from Duke University.

The study, “Effects of corticosteroid treatment on airway inflammation, mechanics, and hyperpolarized 3He magnetic resonance imaging in an allergic mouse model,” looked at how corticosteroid therapy, a steroid treatment used for asthma, worked on mice. It’s been cited four times, according to Thomson Scientific’s Web of Knowledge, and was one of the products of the environmental lung health research conducted by Potts-Kant and Duke professor William Foster, the other co-author on the retracted studies.

Here’s the complete retraction notice: Continue reading Duke University lung researchers cough up fourth retraction, due to “inconsistent” data

Opaque retraction notice for imaging paper

cmmmSometimes we run across retraction notices that are vague, and others that are contorted, but we’ve just found one that gets highest marks for being completely inscrutable.

The article, “Bayes Clustering and Structural Support Vector Machines for Segmentation of Carotid Artery Plaques in Multicontrast MRI,” was written by a group from China and Cambridge University in England — so, we’re thinking language ought not to have been much of a barrier to clear English. It appeared in November 2012 in Computational and Mathematical Methods in Medicine, and describes a way to analyze carotid artery plaque levels in MRI images.

But according to the notice, the technique did not work as planned (or so we think):

Continue reading Opaque retraction notice for imaging paper

Can’t spell Novartis without VART: Drug study retracted for conflict of interest, data issues

JHH(Cover).inddA major scandal in Japan over the Novartis hypertension drug valsartan has resulted in a retraction from the Journal of Human Hypertension. 

Frequent Retraction Watch subject Hiroaki Matsubara resigned his post at Kyoto Prefectural University in 2013, after his work on valsartan was shown to be riddled with data errors and undisclosed conflicts of interest.

Also that year, suspicions about Chiba University hypertension researcher Issei Komuro’s work were first raised by an anonymous blog, which detailed numerous image manipulations in the researcher’s published works. Komuro, who frequently collaborated with Matsubara, has been a senior author on a number of valsartan papers, including the now-retracted one, which reported the results of Novartis-sponsored Valsartan Amlodipine Randomized Trial in 2011 without reporting the Novartis funding.

The paper, which has been cited three times, according to Thomson Scientific’s Web of Knowledge, had already been subject to a correction in 2013:  Continue reading Can’t spell Novartis without VART: Drug study retracted for conflict of interest, data issues

Paper that formed basis of study retracted earlier this year retracted itself, from Science

science dec 2014Back in May, we reported on a retraction from Molecular Cell that referred to a 2012 study the same group had published in Science. (A few weeks later, the lab head told us just how painful the process was.)

Now, the Science paper has been retracted. Here’s the notice: Continue reading Paper that formed basis of study retracted earlier this year retracted itself, from Science

Second expression of concern appears for chemistry group under institutional review

chemsciThe journal Chemical Science has issued an expression of concern over a 2012 article by a pair of Texas researchers whose “unclick reaction” work has been under scrutiny by their institution.

The article, “Homonuclear bond activation using a stable N,N-diamidocarbene,” was written by Kelly M. Wiggins and Christopher W. Bielawski, of UT Austin. It’s the second EoC that we know of for a paper by Wiggins and Bielawski. We covered a previous one, from Science, that appeared in June.

Here’s the notice (pdf): Continue reading Second expression of concern appears for chemistry group under institutional review

Nature issues Expression of Concern for paper by author who threatened to sue Retraction Watch

Ariel Fernandez, via Wikipedia
Ariel Fernandez, via Wikipedia

Nature has issued an Expression of Concern for a paper co-authored by a scientist who threatened to sue us last year for writing about another Expression of Concern for one of his other papers.

Here’s the “Editorial Expression of Concern” for “Non-adaptive origins of interactome complexity:”

Continue reading Nature issues Expression of Concern for paper by author who threatened to sue Retraction Watch

Dr. Oz: Following green coffee bean diet retraction, site scrubbed, “further study is needed”

green coffee beanOn Monday, we were first to report that a study of green coffee bean extract for weight loss touted on the Dr. Oz Show had been retracted.

That story has been widely picked up by the media, including The Washington Post, which yesterday reported that the show had posted a statement about the development: Continue reading Dr. Oz: Following green coffee bean diet retraction, site scrubbed, “further study is needed”

Authors retract green coffee bean diet paper touted by Dr. Oz

green coffee beanTwo authors of a 2012 paper sponsored by a company that made grand claims about green coffee bean extract’s abilities to help people lose weight have retracted it. The study was cited by The Dr. Oz Show, and last month it cost the company a $3.5 million settlement with the Feds.

Here’s the notice for “Randomized, double-blind, placebo-controlled, linear dose, crossover study to evaluate the efficacy and safety of a green coffee bean extract in overweight subjects,” a paper originally published in Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy: Continue reading Authors retract green coffee bean diet paper touted by Dr. Oz

How meta: Paper on errors retracted for “too many stupid mistakes”

Measurement-in-Physical-Education-and-Exercise-ScienceA paper published in Measurement in Physical Education and Exercise Science has been retracted for statistical and typographical mistakes.

Here’s the notice for “Comparing Measurement Error Between Two Different Methods of Measurement of Various Magnitudes”: Continue reading How meta: Paper on errors retracted for “too many stupid mistakes”

Cell line switch sinks PLoS ONE cancer paper

plosWe’ve written before about how common cell line mix ups are in cancer research; according to a 2012 Wall Street Journal article (paywalled), between a fifth and a third of cancer cell lines tested by suspicious researchers turned out to be misidentified.

Obviously, mistakenly studying the wrong kind of cancer is a waste of precious resources, both time and money. And it’s clear the problem hasn’t gone away. PLoS ONE just retracted a cancer paper originally published in December 2012 for studying two cell lines that had been contaminated by other cell types.

Here’s the notice for “Epithelial Mesenchymal Transition Is Required for Acquisition of Anoikis Resistance and Metastatic Potential in Adenoid Cystic Carcinoma”:
Continue reading Cell line switch sinks PLoS ONE cancer paper